Enhanced diagnostic signatures for patient stratification and improved clinical management of human disease.
Welcome to resolomics
Resolomics is a biotechnology company developing innovative, high-value companion diagnostics and a novel cell-based therapy.
Initial product focus is on: Rheumatoid Arthritis, Cardiovascular Disease, Sepsis & Trauma where substantial unmet clinical need exists.
Sepsis & Trauma
Our technology can be applied across all inflammatory diseases, both chronic and acute.
To find out more about Resolomics and our technology, please get in touch with our team.
Enhanced diagnostic signatures for patient stratification and improved clinical management of human diseases
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square
LONDON EC1M 6BQ